A new polychemotherapy regimen has been developed for gastric cancer. Etoposide at the dose of 120 mg/m2 for three days, Epidoxorubicin at the dose of 30 mg/m2 on day 1 and Cisplatin at the dose of 40 mg/m2 on day 2 were administered to 26 advanced gastric patients every two weeks with the support of Granulocyte Colony Stimulating Factor from day 8 to day 12 of each cycle. The treatment was feasible with most cases (21/25) having received at least four cycles with a dose intensity > 85%, without lifethreatening side effects. Toxicity was lower than that observed in the classical combination of Etopside- Anthracycline-Cisplatin.
|Number of pages||4|
|Issue number||5 B|
|Publication status||Published - Sep 1997|
- Gastric cancer dose intensity
- Granulocyte colony stimulating factor
ASJC Scopus subject areas
- Cancer Research